Bladder Cancer

Cell Genesys to Present at the JMP Securities Sector Focus Conference

Bladder Cancer Library Library Home This article was published in Pain & Central Nervous System Week, which you can subscribe to online.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com/. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com/.

Keywords: Biological Therapy, Biotechnology, Biotechnology Business, Biotechnology Company, Bladder Cancer, Bladder Carcinoma, Cell Genesys Inc., Gene Therapy, Immunotherapy, Mental Health, Neurodegenerative, Oncology, Pancreatic Cancer, Pancreatic Neoplasms, Prostate Cancer, Prostatic Neoplasms, Treatment, Cell Genesys Inc.

This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.